Search Result

Results for "

DPDS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Biochemical Assay Reagents (3) Cytochrome P450 (2) Dihydropyrimidine Dehydrogenase (DPD) (6) DNA/RNA Synthesis (5) Drug Derivative (1) Elastase (1) Endogenous Metabolite (7) Environmental Pollutants (1) Isotope-Labeled Compounds (5) Nucleoside Antimetabolite/Analog (3) Reference Standards (4)
By Research Areas:	Cancer (13) Infection (2) Metabolic Disease (6) Neurological Disease (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Nucleoside Analogs (1) Thymidine (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W012926

Dihydrouracil 1 Publications Verification 5,6-Dihydrouracil	Endogenous Metabolite	Metabolic Disease
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W010450

Thymine 1 Publications Verification	Endogenous Metabolite	Metabolic Disease Cancer
Thymine, one of the four bases of DNA, is a substrate for rat liver dihydropyrimidine dehydrogenase (DPD), with a K_m value of 2.2 μM, K_i of 24 μM (using 5-FU as the DPD substrate), and a specific activity of 0.68 nmol/min/mg .

HY-14905

Uridine triacetate Tri-O-acetyl uridine	Drug Derivative	Neurological Disease
Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .

HY-124062

TAS-114 3 Publications Verification	DNA/RNA Synthesis	Cancer
TAS-114 is an orally active dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine .

HY-17469

Gimeracil 3 Publications Verification Gimestat	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-10533

Eniluracil 1 Publications Verification 5-Ethynyluracil; GW776C85	Biochemical Assay Reagents	Cancer
Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits *DPD*, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W012926S1

Dihydrouracil-d4 5,6-Dihydrouracil-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dihydrouracil-d₄ is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-134160

5,6-Dihydro-5-Fluorouracil 5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil	Nucleoside Antimetabolite/Analog	Cancer
5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W196803

Dipropyl disulfide Propyl Disulfide; DPDS	Environmental Pollutants Cytochrome P450	Others
Dipropyl disulfide is oxidized to dipropyl thiosulfinate (DPDSO) by rat microsomes. Both flavincontaining monooxygenases (FMO) and cytochrome P450 enzymes (CYPs) are involved in dipropyl disulfide oxidation. Dipropyl disulfide forms two metabolites: propylglutathione sulfide conjugate and propylthiol .

HY-W001983

5-Iodouracil	Dihydropyrimidine Dehydrogenase (DPD)	Cancer
5-Iodouracil (Compound 4b) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor (IC₅₀=0.22 μM). 5-Iodouracil is promising for research of DPD-overexpressing solid tumors like non-small cell lung cancer (NSCLC) .

HY-W012926S

Dihydrouracil-13C4,15N2 5,6-Dihydrouracil-¹³C₄,¹⁵N₂	Endogenous Metabolite	Metabolic Disease
Dihydrouracil- ¹³C₄, ¹⁵N₂ is the ¹³C and ¹⁵N labeled Dihydrouracil . Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-114249

DFP-11207	Nucleoside Antimetabolite/Analog Dihydropyrimidine Dehydrogenase (DPD)	Cancer
DFP-11207 is an orally active fluoropyrimidine cytotoxic agent. DFP-11207 combines a 5-FU (HY-90006) pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. DFP-11207 can be used for the research of cancer .

HY-134160S

5,6-Dihydro-5-Fluorouracil-13C,15N2 5-DHFU-¹³C,¹⁵N₂; 5-Fluorodihydropyrimidine-2,4-dione-¹³C,¹⁵N₂; 5-Fluorodihydrouracil-¹³C,¹⁵N₂	Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog	Cancer
5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W012926R

Dihydrouracil (Standard) 5,6-Dihydrouracil (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Dihydrouracil (Standard) is the analytical standard of Dihydrouracil. This product is intended for research and analytical applications. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[1][2].

HY-W196803R

Dipropyl disulfide (Standard) Propyl Disulfide (Standard); DPDS (Standard)	Cytochrome P450 Reference Standards	Others
Dipropyl disulfide is oxidized to dipropyl thiosulfinate (DPDSO) by rat microsomes. Both flavincontaining monooxygenases (FMO) and cytochrome P450 enzymes (CYPs) are involved in dipropyl disulfide oxidation. Dipropyl disulfide forms two metabolites: propylglutathione sulfide conjugate and propylthiol .

HY-W014109

(E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione (E)-5-(2-Bromovinyl)uracil; BVU	DNA/RNA Synthesis	Infection
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.

HY-10533R

Eniluracil (Standard) 5-Ethynyluracil (Standard); GW776C85 (Standard)	Biochemical Assay Reagents Reference Standards	Cancer
Eniluracil (Standard) is the analytical standard of Eniluracil. This product is intended for research and analytical applications. Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits DPD, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-17469R

Gimeracil (Standard) Gimestat (Standard)	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Reference Standards	Cancer
Gimeracil (Standard) is the analytical standard of Gimeracil. This product is intended for research and analytical applications. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W777340

Gimeracil-13C3 Gimestat-¹³C₃	Isotope-Labeled Compounds DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil- ¹³C₃ (Gimestat- ¹³C₃) is the ¹³C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-17469S

Gimeracil-13C3,15N Gimestat-¹³C₃,¹⁵N	Isotope-Labeled Compounds	Cancer
Gimeracil- ¹³C₃, ¹⁵N (Gimestat- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W779020

Dihydrouracil-13C,15N2 5,6-Dihydrouracil-¹³C,¹⁵N₂	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dihydrouracil- ¹³C, ¹⁵N₂ (5,6-Dihydrouracil- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Dihydrouracil (HY-W012926). Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-19413

Ro-09-4889	Dihydropyrimidine Dehydrogenase (DPD) Endogenous Metabolite	Cancer
Ro-09-4889 is a prodrug. Ro-09-4889 can inhibit dihydropyrimidine dehydrogenase (DPD) activity and its effect is dose-dependent. Ro-09-4889 can be used for cancer research .

HY-182942

*PV-DPD-19*	Bacterial Elastase	Infection
PV-DPD-19 is an autoinducer-2 (AI-2) quorum sensing inhibitor. PV-DPD-19 reduces AI-2 production and inhibits the expression of multiple MSCRAMMs. In co-culture systems with Staphylococcus aureus, PV-DPD-19 decreases the production of pyocyanin and Elastase in Pseudomonas aeruginosa. PV-DPD-19 impairs the adhesion ability of Staphylococcus aureus to lung epithelial cells. PV-DPD-19 inhibits biofilm formation of Pseudomonas aeruginosa (MBIC₅₀ = 27 μg/mL) and Staphylococcus aureus (MBIC₅₀ = 35 μg/mL). PV-DPD-19 shows no cytotoxicity in both in vitro lung epithelial cell models and in vivo Galleria mellonella larva models .

HY-179188

DPD Medium	Biochemical Assay Reagents	Others
DPD Medium is mainly used for tissue culture and protoplast culture of woody plants, especially trees.

DPD Medium	Biochemical Assay Reagents
DPD Medium is mainly used for tissue culture and protoplast culture of woody plants, especially trees.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W012926

Dihydrouracil 1 Publications Verification 5,6-Dihydrouracil	Natural Products Microorganisms Classification of Application Fields Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W012926R

Dihydrouracil (Standard) 5,6-Dihydrouracil (Standard)	Structural Classification Natural Products Microorganisms Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dihydrouracil (Standard) is the analytical standard of Dihydrouracil. This product is intended for research and analytical applications. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[1][2].

Cat. No.	Product Name	Chemical Structure

HY-W012926S1

Dihydrouracil-d4
Dihydrouracil-d₄ is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W012926S

Dihydrouracil-13C4,15N2
Dihydrouracil- ¹³C₄, ¹⁵N₂ is the ¹³C and ¹⁵N labeled Dihydrouracil . Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-134160S

5,6-Dihydro-5-Fluorouracil-13C,15N2
5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

5,6-Dihydro-5-Fluorouracil-13C,15N2

5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W777340

Gimeracil-13C3
Gimeracil- ¹³C₃ (Gimestat- ¹³C₃) is the ¹³C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-17469S

Gimeracil-13C3,15N
Gimeracil- ¹³C₃, ¹⁵N (Gimestat- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W779020

Dihydrouracil-13C,15N2
Dihydrouracil- ¹³C, ¹⁵N₂ (5,6-Dihydrouracil- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Dihydrouracil (HY-W012926). Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

Cat. No.	Product Name		Classification

HY-10533

Eniluracil 1 Publications Verification 5-Ethynyluracil; GW776C85		Alkynes
Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits *DPD*, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-W010450

Thymine 1 Publications Verification		Nucleoside Analogs Thymidine
Thymine, one of the four bases of DNA, is a substrate for rat liver dihydropyrimidine dehydrogenase (DPD), with a K_m value of 2.2 μM, K_i of 24 μM (using 5-FU as the DPD substrate), and a specific activity of 0.68 nmol/min/mg .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

DPDS

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products